According to the report, the market is expected to reach USD 8.53bn by 2023 from an estimated USD 6.40bn in 2018, at a CAGR of 5.9% during the forecast period.
Factors such as the growing pharmaceutical market with the rapidly aging population and increasing incidence of chronic disease, advancements in functional excipients, growing generics market propelled by the patent cliffs, and the rapidly growing biopharmaceuticals sector are driving the growth of the pharmaceutical excipients market.
The emergence of multifunctional and co-processed excipients, shifting focus of pharmaceutical manufacturing to emerging markets, and the growing biosimilars industry also present significant opportunities for the growth of excipients.
However, the increasing regulatory stringency, cost and time-intensive drug development process, and the quality concerns of excipient manufacturers represent a significant challenge to the market growth.
MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.
The company currently services 5000 customers worldwide, with 850 full-time analyst tracking global high growth markets.
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic